Rocket Pharmaceuticals
Rocket Pharmaceuticals reported revenue of $0 million in fiscal 2025. Free cash flow was −$190 million. The diluted share count rose 17.2%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Rocket Pharmaceuticals does
Rocket Pharmaceuticals is a late-stage biotechnology company that develops gene therapies for rare, often fatal inherited diseases. A gene therapy delivers a working copy of a gene into a patient's cells. Rocket has no approved products and no product sales. Its work now centers on heart diseases caused by a single gene, using harmless modified viruses called AAV vectors to deliver the gene.
Its lead cardiovascular candidate, RP-A501, is for Danon disease, a rare inherited disorder that causes heart failure. Its other programs target forms of inherited heart disease. It also has KRESLADI, an investigational gene therapy for a rare immune disorder called LAD-I, which uses a patient's own modified blood stem cells. The FDA issued a complete response letter for it, and the company has submitted responses. It says it plans a scaled commercial effort for that very small patient group.
In July 2025, Rocket restructured and cut back its pipeline, de-prioritizing its Fanconi anemia and pyruvate kinase deficiency programs. It reduced its workforce by about 30%. It runs its own manufacturing plant in Cranbury, New Jersey. At December 31, 2025, it had 202 full-time employees.
Its biggest risks, as it describes them
- It has lost money in every period and will need more funding, which may not be available on acceptable terms.
- Its gene therapies use new technology, and trials may be delayed or fail to show safety and effectiveness.
- It may never win approval for its candidates in the U.S. or EU, including KRESLADI after its FDA letter.
- Its restructuring may not save as much as it expects, and it faces securities lawsuits.
- Production problems or rule violations at its own manufacturing facilities could delay or limit supply.
Income statement
Rocket Pharmaceuticals lost money in fiscal 2025: a net loss of $223 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 389 | 356 | 408 | 372 | 189 |
| Debt incl. finance leases | 21 | 21 | 21 | 21 | 21 |
| Net debt (negative means net cash) | −368 | −335 | −386 | −351 | −168 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.0x | 0.0x | 0.1x | 0.1x |
| Interest coverage | −56.2x | −120.5x | −138.5x | −144.9x | −122.5x |
| Current ratio | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
| Quick ratio | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
Cash flow
Projections
Project Rocket Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Rocket Pharmaceuticals says to expect
- Cash: funding of planned operations
Based on its current operating plan, Rocket expects its cash, cash equivalents and investments as of September 30, 2026, to fund operations into the third quarter of 2028.
- Pivotal trial: dosing and results timing
Rocket expects to complete pivotal trial dosing by mid-2027, with topline results anticipated in mid-2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $34,400 of Rocket Pharmaceuticals shares on the open market, and 5 insiders sold $845,572.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Martin WilsonGeneral Counsel | Sold | 4,087 | $2.25 | $9,196 | Form 4 |
| Nov 13, 2026 | Gaurav ShahCEO | Sold | 3,020 | $2.25 | $6,795 | Form 4 |
| Sep 11, 2026 | Martin WilsonGeneral Counsel | Sold | 75,364 | $3.40 | $256,238 | Form 4 |
| Aug 18, 2026 | Gaurav ShahCEO | Sold | 2,293 | $3.38 | $7,750 | Form 4 |
| Aug 18, 2026 | Martin WilsonGeneral Counsel | Sold | 631 | $3.38 | $2,133 | Form 4 |
| Aug 13, 2026 | Martin WilsonGeneral Counsel | Sold | 3,493 | $3.38 | $11,806 | Form 4 |
| Aug 13, 2026 | Gaurav ShahCEO | Sold | 2,837 | $3.38 | $9,589 | Form 4 |
| Aug 11, 2026 | Christopher James StevensChief Operating Officer | Sold | 36,658 | $3.50 | $128,303 | Form 4 |
| Aug 11, 2026 | Sarbani ChaudhuriSee Remarks | Sold | 4,701 | $3.50 | $16,454 | Form 4 |
| May 21, 2026 | Gaurav ShahCEO | Sold | 55,684 | $3.09 | $172,064 | Form 4 |
| May 19, 2026 | Gaurav ShahCEO | Sold | 2,409 | $3.01 | $7,251 | Form 4 |
| May 19, 2026 | Martin WilsonGeneral Counsel | Sold | 662 | $3.01 | $1,993 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 2 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | 2.23 | 0.74 | −10.24 |
| Accruals ratio | −9.1% | −9.0% | −7.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 2 of 8 | 2 of 8 | 2 of 8 |
Compare
Put Rocket Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rocket Pharmaceuticals | FY25 | — | — | — | −165.1% | — | 2 | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 6 | 15 | 53 | 58 | 105 | 126 | 166 | 186 | 171 | 142 |
| Operating income | −8 | −20 | −71 | −76 | −134 | −167 | −224 | −260 | −273 | −232 |
| Net income | −8 | −20 | −74 | −77 | −140 | −169 | −222 | −246 | −259 | −223 |
| Diluted EPS (US$) | −1.11 | −2.88 | −1.89 | −1.58 | −2.52 | −2.67 | −3.26 | −2.92 | −2.73 | −2.01 |
| Diluted shares (millions) | 7 | 7 | 39 | 49 | 55 | 63 | 68 | 84 | 95 | 111 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −16 | −54 | −65 | −75 | −121 | −178 | −195 | −210 | −190 |
| Capital expenditure | 0 | 1 | 2 | 23 | 21 | 8 | 8 | 16 | 6 | 0 |
| Free cash flow | −6 | −17 | −55 | −88 | −95 | −129 | −186 | −211 | −216 | −190 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 1 | 14 | 13 | 19 | 29 | 31 | 39 | 44 | 37 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 126 | 100 | 213 | 304 | 483 | 389 | 356 | 408 | 372 | 189 |
| Debt incl. finance leases | — | 0 | 41 | 45 | 56 | 21 | 21 | 21 | 21 | 21 |
| Total assets | 130 | 20 | 251 | 372 | 591 | 497 | 552 | 566 | 528 | 330 |
| Total liabilities | 56 | 5 | 57 | 65 | 87 | 42 | 62 | 74 | 64 | 53 |
| Shareholders' equity | 8 | 16 | 194 | 307 | 504 | 455 | 490 | 493 | 463 | 277 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | −170.4% | −170.1% | −161.8% | −147.0% | −157.5% | −197.7% | −165.1% |
| Return on equity | −63.3% | −163.9% | −71.1% | −30.8% | −34.5% | −35.3% | −47.0% | −50.0% | −54.1% | −60.3% |
| Return on assets | −6.2% | −26.1% | −54.9% | −24.8% | −29.0% | −31.1% | −42.3% | −43.9% | −47.3% | −52.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |